Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.84 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.77 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.77 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.77 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28992834 | 1.00 | SCN9A (0.84) | SCN9AP2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL4595935 | 0.92 | SCN9A (1.00) | SCN9AP2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL5658896 | 0.86 | SCN9A (0.65) | SCN9AP2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL28992818 | 0.85 | SCN9A (0.74) | SCN9AP2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL28992820 | 0.85 | SCN9A (0.74) | SCN9AP2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL5658331 | 0.84 | SCN9A (0.62) | SCN9AP2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL20553581 | 0.84 | SCN9A (0.62) | SCN9AP2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL14533506 | 0.82 | SCN9A (0.81) | SCN9AP2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL4731135 | 0.81 | SCN9A (1.00) | SCN9A | |
| SCHEMBL5658410 | 0.80 | SCN9A (0.57) | SCN9AP2RX1P2RX3P2RX4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115873034-A | Semi-active phosphamide ligand and preparation method thereof | 上海毕臣生化科技有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | NR3C2, NR5A1, NR5A2 | SCN9A 1918/4885P2RX1 2141/4885P2RX3 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.